Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 8/20 | 0.48 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.48 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.41 |
| ▸ | PRKACA | P17612 | 1/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.41 |
| ▸ | MARK3 | P27448 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.41 |
| ▸ | CLK2 | P49760 | 1/20 | 0.41 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.41 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.41 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.41 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16236456 | 0.86 | ADK (0.43) | ADKSLC29A1DYRK3ROCK2PRKD3 | |
| SCHEMBL16236531 | 0.84 | ADK (0.44) | ADKSLC29A1DYRK3ROCK2PRKD3 | |
| SCHEMBL16236535 | 0.84 | ADK (0.44) | ADKSLC29A1DYRK3ROCK2PRKD3 | |
| SCHEMBL24072919 | 0.83 | ADK (0.46) | ADKSLC29A1SRCLCKTEK | |
| SCHEMBL28589607 | 0.82 | ADK (0.42) | ADKSLC29A1DYRK3ROCK2PRKD3 | |
| SCHEMBL8445449 | 0.81 | ADK (0.44) | ADKSLC29A1DYRK3ROCK2PRKD3 | |
| SCHEMBL23966679 | 0.81 | DYRK3 (0.60) | ADKDYRK3ROCK2PRKD3MAP4K4 | |
| SCHEMBL29032350 | 0.81 | DYRK3 (0.41) | ADKSLC29A1DYRK3ROCK2PRKD3 | |
| SCHEMBL16236999 | 0.81 | ADK (0.46) | ADKSLC29A1DYRK3ROCK2PRKD3 | |
| SCHEMBL29503417 | 0.81 | ADK (0.46) | ADKSLC29A1DYRK3ROCK2PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713321-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713321-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713321-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| CN-113683629-B | Substituted heteroaryl compounds, compositions and uses thereof | 北京范恩柯尔生物科技有限公司 | 2023-07-04 | — | — | CN | disclosed |
| US-20230129710-A1 | Methods and Reagents for Synthesizing Nucleosides and Analogues Thereof | SIMON FRASER UNIVERSITY (CA) | 2023-04-27 | — | — | US | disclosed |
| US-20230129710-A1 | Methods and Reagents for Synthesizing Nucleosides and Analogues Thereof | SIMON FRASER UNIVERSITY (CA) | 2023-04-27 | — | — | US | disclosed |
| CN-115843272-A | Inhibitors of NEK7 kinase | 哈利亚治疗公司 | 2023-03-24 | — | — | CN | disclosed |
| WO-2021242505-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. (US) | 2021-12-02 | — | — | WO | disclosed |
| CN-113683629-A | Substituted heteroaryl compounds, compositions and uses thereof | 北京范恩柯尔生物科技有限公司 | 2021-11-23 | — | — | CN | disclosed |
| US-20210355130-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. | 2021-11-18 | — | — | US | disclosed |
| US-11161852-B1 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2021-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129710-A1 | Methods and Reagents for Synthesizing Nucleosides and Analogues Thereof | NUDT1, ADAR, APRT | ADK 149/4885SLC29A1 29/4885DYRK3 2851/4885 |
| US-20210355130-A1 | INHIBITORS OF NEK7 KINASE | NEK7, NEK1, NEK5 | ADK 72/4885SLC29A1 1626/4885DYRK3 580/4885 |
| US-11713321-B2 | Inhibitors of NEK7 kinase | NEK7, NEK1, NEK5 | ADK 72/4885SLC29A1 1626/4885DYRK3 580/4885 |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | ADK 286/4885SLC29A1 2077/4885DYRK3 3229/4885 |
| US-11161852-B1 | Inhibitors of NEK7 kinase | NEK7, NEK1, NEK5 | ADK 72/4885SLC29A1 1626/4885DYRK3 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.